肺癌分子靶向治疗的现状与进展  

Current status and advances of molecular targeted therapy for lung cancer

作　　者：周航（综述）[1] 梅同华[1] 赵麟丰（审校）[1] 

机构地区：[1]重庆医科大学附属第二医院呼吸内科,400010

出　　处：《国际肿瘤学杂志》2007年第7期493-496,共4页Journal of International Oncology

摘　　要：分子靶向药物是利用肿瘤细胞和正常细胞之间分子细胞生物学上的差异，采用封闭受体、抑制血管生成、阻断信号传导通路等方法作用于肿瘤细胞的特定靶点，特异性地抑制肿瘤细胞的生长，促使肿瘤细胞凋亡。分子靶向治疗比传统的化疗特异性强，不良反应小，将成为以后肿瘤治疗的新趋势。With the increased understanding of molecular mechanisms and basic pathways in the pathogenesis of tumors, targeted molecular therapy shows an important complement to other existing cancer therapies. Such molecular targeted therapy depends on the difference between the cancer cells and normal cells, and aims specifically to inhibit the tumor growth and to promote the apoptosis of tumor cells by blocking receptors, nihibiting angiogenesis and blocking intracellular signal network. Molecular targeted therapy is more specific, and has less side effect on normal cells of the bodv.comnared with traditional chemotheranv. This review focuses on advances of several molecular targeted agents that are in the clinical trial phases and on themarketing in the treatment of the non-small cell lung cancer.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 血管内皮生长因子类 基质金属蛋白酶类 

分 类 号：R734.2[医药卫生—肿瘤] R730.54[医药卫生—临床医学]